2021 FDA TIDES (Peptides and Oligonucleotides) Harvest.
2021 FDA TIDES (Peptides and Oligonucleotides) Harvest.
复制标题
DOI：
10.3390/ph15020222
复制
发表时间：
2022-02-13
期刊：
影响因子：
--
通讯作者：
de la Torre BG
中科院分区：
文献类型：
--
作者：
Al Shaer D;Al Musaimi O;Albericio F;de la Torre BG
从医学、医药和社会的角度来看，2021年是新冠肺炎疫情的主导年。然而，尽管发生了这场全球健康危机，制药业仍在继续努力，就美国食品和药物管理局(FDA)接受的药物而言，2021年可以被认为是出色的一年。因此，在这一年里，FDA已经批准了50种新药，其中36种是新的化学实体，14种是生物制品。它还批准了10个肽(8个肽，2个寡核苷酸)，以及2个结构含有多肽的抗体-药物结合物(ADCs)。因此，潮汐约占各种药物类别批准的24%。重要的是，这一百分比已经超过了2020年的数字(10%)，从而反映了浪潮的显著成功。本文从化学结构、药物靶点、作用方式、给药途径和不良反应等方面对已批准的潮汐类药物进行了分析。
From the medical, pharmaceutical, and social perspectives, 2021 has been a year dominated by the COVID-19 pandemic. However, despite this global health crisis, the pharmaceutical industry has continued its endeavors, and 2021 could be considered an excellent year in terms of the drugs accepted by the US Food and Drug Administration (FDA). Thus, during this year, the FDA has approved 50 novel drugs, of which 36 are new chemical entities and 14 biologics. It has also authorized 10 TIDES (8 peptides, 2 oligonucleotides), in addition to 2 antibody-drug conjugates (ADCs) whose structures contain peptides. Thus, TIDES have accounted for about 24% of the approvals in the various drug categories. Importantly, this percentage has surpassed the figure in 2020 (10%), thus reflecting the remarkable success of TIDES. In this review, the approved TIDE-based drugs are analyzed on the basis of their chemical structure, medical target, mode of action, administration route, and adverse effects.
影响因子：
3.1
作者：
Banerjee, Yajnavalka;Pantea Stoian, Anca;Rizzo, Manfredi
通讯作者：
Rizzo, Manfredi
DOI：
10.3390/ph14020145
发表时间：
2021-02-11
期刊：
Pharmaceuticals (Basel, Switzerland)
影响因子：
--
作者：
Al Musaimi O;Al Shaer D;Albericio F;de la Torre BG
通讯作者：
de la Torre BG
2017 FDA肽收获。
DOI：
10.3390/ph11020042
发表时间：
2018-05-07
期刊：
Pharmaceuticals (Basel, Switzerland)
影响因子：
--
作者：
Al Musaimi O;Al Shaer D;de la Torre BG;Albericio F
通讯作者：
Albericio F